HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe.
HCV
HIV
direct-acting antivirals
interferon
reinfection
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
22
09
2021
received:
02
07
2021
accepted:
10
11
2021
pubmed:
10
12
2021
medline:
10
6
2022
entrez:
9
12
2021
Statut:
ppublish
Résumé
Although direct-acting antivirals (DAAs) can clear HCV in nearly all HIV/HCV-coinfected individuals, high rates of reinfection may hamper efforts to eliminate HCV in this population. We investigated reinfection after sustained virological response (SVR) in HIV/HCV-coinfected individuals in Europe. Factors associated with odds of reinfection by 2 years after SVR in EuroSIDA participants with one or more HCV-RNA test and 2 years follow-up were assessed using logistic regression. Overall, 1022 individuals were included. The median age was 50 (interquartile range: 43-54 years), and most were male (78%), injection drug users (52%), and received interferon (IFN)-free DAAs (62%). By 24 months, 75 [7.3%, 95% confidence interval (CI): 5.7-8.9%] individuals were reinfected. Among individuals treated prior to 2014, 16.1% were reinfected compared with 4.2% and 8.3%, respectively, among those treated during or after 2014 with IFN-free and IFN-based therapy. After adjustment, individuals who had started treatment during or after 2014 with IFN-free or IFN-based therapy had significantly lower odds of reinfection (adjusted odds ratio = 0.21, 95% CI: 0.11-0.38; 0.43, 95% CI: 0.22-0.83) compared with those who had received therapy before 2014. There were no significant differences in odds of reinfection according to age, gender, European region, HIV transmission risk group or liver fibrosis. Among HIV/HCV-coinfected individuals in Europe, 7.3% were reinfected with HCV within 24 months of achieving SVR, with evidence suggesting that this is decreasing over time and with use of newer HCV regimens. Harm reduction to reduce reinfection and surveillance to detect early reinfection with an offer of treatment are essential to eliminate HCV.
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
684-692Investigateurs
A Harxhi
(A)
M Losso
(M)
M Kundro
(M)
B Schmied
(B)
R Zangerle
(R)
I Karpov
(I)
A Vassilenko
(A)
V M Mitsura
(VM)
D Paduto
(D)
N Clumeck
(N)
S De Wit
(S)
M Delforge
(M)
E Florence
(E)
L Vandekerckhove
(L)
V Hadziosmanovic
(V)
J Begovac
(J)
L Machala
(L)
D Jilich
(D)
D Sedlacek
(D)
G Kronborg
(G)
T Benfield
(T)
J Gerstoft
(J)
T Katzenstein
(T)
C Pedersen
(C)
I S Johansen
(IS)
L Ostergaard
(L)
L Wiese
(L)
N F Moller
(NF)
L N Nielsen
(LN)
K Zilmer
(K)
Jelena Smidt
(J)
I Aho
(I)
J-P Viard
(JP)
P-M Girard
(PM)
C Pradier
(C)
E Fontas
(E)
C Duvivier
(C)
J Rockstroh
(J)
G Behrens
(G)
O Degen
(O)
H J Stellbrink
(HJ)
C Stefan
(C)
J Bogner
(J)
G Fätkenheuer
(G)
N Chkhartishvili
(N)
H Sambatakou
(H)
G Adamis
(G)
N Paissios
(N)
J Szlávik
(J)
M Gottfredsson
(M)
E Devitt
(E)
L Tau
(L)
D Turner
(D)
M Burke
(M)
E Shahar
(E)
G Hassoun
(G)
H Elinav
(H)
M Haouzi
(M)
D Elbirt
(D)
A D'Arminio Monforte
(A)
R Esposito
(R)
I Mazeu
(I)
C Mussini
(C)
F Mazzotta
(F)
A Gabbuti
(A)
A Lazzarin
(A)
A Castagna
(A)
N Gianotti
(N)
M Galli
(M)
A Ridolfo
(A)
L Sacco
(L)
V Uzdaviniene
(V)
R Matulionyte
(R)
T Staub
(T)
R Hemmer
(R)
S Dragas
(S)
M Stevanovic
(M)
P Reiss
(P)
J Trajanovska
(J)
D H Reikvam
(DH)
A Maeland
(A)
J Bruun
(J)
B Knysz
(B)
J Gasiorowski
(J)
M Inglot
(M)
E Bakowska
(E)
R Flisiak
(R)
A Grzeszczuk
(A)
M Parczewski
(M)
K Maciejewska
(K)
B Aksak-Was
(B)
M Beniowski
(M)
E Mularska
(E)
E Jablonowska
(E)
J Kamerys
(J)
K Wojcik
(K)
I Mozer-Lisewska
(I)
B Rozplochowski
(B)
A Zagalo
(A)
K Mansinho
(K)
F Maltez
(F)
R Radoi
(R)
C Oprea
(C)
Carol Davila
(C)
A Yakovlev
(A)
T Trofimora
(T)
I Khromova
(I)
E Kuzovatova
(E)
I N Blokhina
(IN)
Nizhny Novogrod
(N)
E Borodulina
(E)
E Vdoushkina
(E)
J Ranin
(J)
J Tomazic
(J)
J M Miro
(JM)
J M Miró
(JM)
E Martinez
(E)
F Garcia
(F)
J L Blanco
(JL)
M Martinez-Rebollar
(M)
J Mallolas
(J)
P Callau
(P)
J Rojas
(J)
A Inciarta
(A)
S Moreno
(S)
S Del Campo
(S)
B Clotet
(B)
A Jou
(A)
R Paredes
(R)
J Puig
(J)
J M Llibre
(JM)
J R Santos
(JR)
P Domingo
(P)
M Gutierrez
(M)
G Mateo
(G)
M A Sambeat
(MA)
J M Laporte
(JM)
K Falconer
(K)
A Thalme
(A)
A Sonnerborg
(A)
J Brannstrom
(J)
L Flamholc
(L)
A Scherrer
(A)
R Weber
(R)
M Cavassini
(M)
A Calmy
(A)
H Furrer
(H)
M Battegay
(M)
P Schmid
(P)
A Kuznetsova
(A)
J Mikhalik
(J)
M Sluzhynska
(M)
A Milinkovic
(A)
A M Johnson
(AM)
E Simons
(E)
S Edwards
(S)
A Phillips
(A)
M A Johnson
(MA)
A Mocroft
(A)
C Orkin
(C)
A Winston
(A)
A Clarke
(A)
C Leen
(C)
I Karpov
(I)
M Losso
(M)
J Lundgren
(J)
J Rockstroh
(J)
I Aho
(I)
L D Rasmussen
(LD)
V Svedhem
(V)
G Wandeler
(G)
C Pradier
(C)
N Chkhartishvili
(N)
R Matulionyte
(R)
C Oprea
(C)
J D Kowalska
(JD)
J Begovac
(J)
J M Miró
(JM)
G Guaraldi
(G)
R Paredes
(R)
G Wandeler
(G)
R Paredes
(R)
L Peters
(L)
O Kirk
(O)
L Peters
(L)
A Bojesen
(A)
D Raben
(D)
E V Hansen
(EV)
D Kristensen
(D)
J F Larsen
(JF)
A H Fischer
(AH)
A Mocroft
(A)
A Phillips
(A)
A Cozzi-Lepri
(A)
S Amele
(S)
A Pelchen-Matthews
(A)
A Roen
(A)
E Tusch
(E)
W Bannister
(W)
J Reekie
(J)
Informations de copyright
© 2021 British HIV Association.
Références
Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889-1898.
Accessed July 2, 2021. https://apps.who.int/iris/bitstream/handle/10665/206453/WHO_HIV_2016.04_eng.pdf;jsessionid=D4568E7F1B7FB3E11532F729CCBB35E9?sequence=1. In: 2021.
Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis. 2015;61(5):730-740.
Ingiliz P, Wehmeyer MH, Boesecke C, et al. Reinfection with the hepatitis C virus in men who have sex with men after successful treatment with direct-acting antivirals in Germany: current incidence rates, compared with rates during the interferon era. Clin Infect Dis. 2020;71(5):1248-1254.
Berenguer J, Gil-Martin A, Jarrin I, et al. Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV/hepatitis C virus coinfected individuals. AIDS. 2019;33(4):685-689.
Hosseini-Hooshyar S, Martinello M, Yee J, et al. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV. AIDS. 2020;34(9):1347-1358.
Young J, Rossi C, Gill J, et al. Risk factors for hepatitis C virus reinfection after sustained virologic response in patients coinfected with HIV. Clin Infect Dis. 2017;64(9):1154-1162.
Laut K, Kirk O, Rockstroh J, et al. The EuroSIDA study: 25 years of scientific achievements. HIV Med. 2020;21(2):71-83.
Peters L, Mocroft A, Lundgren J, Grint D, Kirk O, Rockstroh J. HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective. BMC Infect Dis. 2014;14(Suppl 6):S13.
Grint D, Peters L, Rockstroh JK, et al. Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals. AIDS. 2015;29(10):1205-1215.
Braun DL, Hampel B, Ledergerber B, et al. A treatment as prevention trial to eliminate hepatitis C among men who have sex with men living with HIV in the Swiss HIV cohort study. Clin Infect Dis. 2020;73(7):e2194-e2202.
Boerekamps A, van den Berk GE, Lauw FN, et al. Declining hepatitis C virus (HCV) incidence in Dutch human immunodeficiency virus-positive men who have sex with men after unrestricted access to HCV therapy. Clin Infect Dis. 2018;66(9):1360-1365.
Larney S, Peacock A, Leung J, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Health. 2017;5(12):e1208-e1220.
Sarrazin C, Isakov V, Svarovskaia ES, et al. Late relapse versus hepatitis C virus reinfection in patients with sustained virologic response after sofosbuvir-based therapies. Clin Infect Dis. 2017;64(1):44-52.
Medrano J, Barreiro P, Resino S, et al. Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients. Clin Infect Dis. 2009;49(9):1397-1401.